Important Information Regarding EGRIFTA SV™ (tesamorelin for injection) and COVID-19 Pandemic.
Our primary objective at Theratechnologies is to ensure the health of Persons with HIV and the continuity of care for any patient in need of EGRIFTA SV™ during the COVID-19 period. We are here to assist you and your team in any way that we can.
For patients in need of EGRIFTA SV™ every step has been taken to assure new patients will be taken care of.
For current EGRIFTA SV™ patients, we are fully prepared to support them in light of the COVID-19 situation.
Should you have any question related to EGRIFTA SV™, we are here to help through THERA patient support® (1-833-238-4372, Mon-Fri 8:30AM-8:00PM ET). We provide support in the form of injection training, insurance coverage analysis and co-pay assistance.
Rest assured that we presently have enough inventory, here in the U.S., for all currently prescribed and new EGRIFTA SV™ patients during the next 12 months. In addition, the production is not affected for EGRIFTA SV™ at this stage by the COVID-19 situation.
The full Prescribing Information and Important Safety Information about EGRIFTA SV™ are available here.
EGRIFTA SV is a trademark of Theratechnologies Inc. THERA patient support is a registered trademark of Theratechnologies Inc.